<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01423643</url>
  </required_header>
  <id_info>
    <org_study_id>NA00033421</org_study_id>
    <secondary_id>R01DA013806</secondary_id>
    <nct_id>NCT01423643</nct_id>
  </id_info>
  <brief_title>HCV/HIV Coinfection: Antiviral Therapy and Fibrosis</brief_title>
  <official_title>HCV/HIV Coinfection: Antiviral Therapy and Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chief purpose of this research is to understand how antiretroviral therapy (ART) affects
      progression of liver disease in persons co-infected with HIV and hepatitis C virus (HCV). The
      investigators study liver disease progression in a cohort of dually infected persons
      according to the success of ART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled subjects will complete questionnaires concerning health status, lifestyle, and
      alcohol/drug use. Participants will undergo liver elastography every 6-12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fibrosis stage</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Liver histologic fibrosis stage (Ishak 0 - 6)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Body composition measurements, derived from DEXA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver stiffness</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Liver stiffness, derived from liver elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Serum levels of various chemical markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver histology</measure>
    <time_frame>up to 15 years</time_frame>
    <description>Liver histology as described by a pathologist</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1250</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Main cohort</arm_group_label>
    <description>Adults infected with both HIV and Hepatitis C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>Adults at risk for liver disease, but not infected with both HIV and Hepatitis C</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen serum and plasma samples. Liver biopsy fixed slides.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with HIV and Hepatitis C in the metropolitan Baltimore area. Preference given to
        those enrolled in the Johns Hopkins Infectious Diseases Outpatient Clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Co-Infected Arm

          1. Subject must be an HIV/HCV co-infected adult with HIV infection diagnosed by antibody
             testing and chronic HCV infection diagnosed by reactive HCV antibody and detectable
             plasma HCV RNA.

          2. Subject must receive medical care at the JHU HIV clinic or through the Viral Hepatitis
             Center.

          3. Subjects previously enrolled in the study cohort, but not currently receiving care in
             the Moore Clinic, may continue in the study.

          4. Females of childbearing potential must be willing to undergo a urine or serum
             pregnancy test.

          5. Subject must be able to provide informed written consent.

        Control Arm

          1. Subject must have or be at risk of having medical conditions that increase the risk of
             liver disease. These include, but are not limited to, HIV mono-infection, HCV
             mono-infection, Hepatitis B infection, alcohol addiction, and/or non-alcoholic
             steatohepatitis.

          2. Females of childbearing potential must be willing to undergo a urine or serum
             pregnancy test.

          3. Subject must be able to provide informed written consent.

        Exclusion Criteria:

          1. To avoid risks associated with ionizing radiation, female subjects may not be pregnant
             or breast feeding at the time of DEXA scanning. To avoid unknown risks to the fetus,
             female subjects may not be pregnant at the time of liver biopsy or FibroScan.

          2. To avoid interference with the DEXA scan, the subject may not have undergone a nuclear
             medicine exam with the past week and/or may not have undergone an x-ray procedure with
             contrast solution within the past 72 hours.

          3. To avoid unknown risks, subjects with an implanted cardiac device such as a
             defibrillator or pacemaker may not undergo FibroScan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L. Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Salgado M, Kirk GD, Cox A, Rutebemberwa A, Higgins Y, Astemborski J, Thomas DL, Thio CL, Sulkowski MS, Blankson JN. Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS. 2011 Jan 28;25(3):385-7. doi: 10.1097/QAD.0b013e328341b86a.</citation>
    <PMID>21099664</PMID>
  </reference>
  <reference>
    <citation>Brown TT, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS. Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. AIDS. 2010 Mar 27;24(6):811-7. doi: 10.1097/QAD.0b013e3283333651.</citation>
    <PMID>20186036</PMID>
  </reference>
  <reference>
    <citation>Balagopal A, Ray SC, De Oca RM, Sutcliffe CG, Vivekanandan P, Higgins Y, Mehta SH, Moore RD, Sulkowski MS, Thomas DL, Torbenson MS. Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS. 2009 Nov 27;23(18):2397-404. doi: 10.1097/QAD.0b013e3283324344.</citation>
    <PMID>19773633</PMID>
  </reference>
  <reference>
    <citation>Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, Higgins Y, Moore RD, Afdhal N, Torbenson M, Sulkowski M, Thomas DL. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis. 2009 Apr 1;48(7):963-72. doi: 10.1086/597350.</citation>
    <PMID>19236273</PMID>
  </reference>
  <results_reference>
    <citation>El-Maouche D, Mehta SH, Sutcliffe C, Higgins Y, Torbenson MS, Moore RD, Thomas DL, Sulkowski MS, Brown TT. Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol. 2011 Oct;55(4):770-6. doi: 10.1016/j.jhep.2011.01.035. Epub 2011 Feb 19.</citation>
    <PMID>21338640</PMID>
  </results_reference>
  <results_reference>
    <citation>Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology. 2011 Mar;140(3):809-17. doi: 10.1053/j.gastro.2010.11.052. Epub 2010 Dec 4.</citation>
    <PMID>21134375</PMID>
  </results_reference>
  <results_reference>
    <citation>Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, Moore RD, Afdhal NH, Thomas DL. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007 Oct 18;21(16):2209-16.</citation>
    <PMID>18090048</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, Thomas DL, Sulkowski MS. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006 Nov 28;20(18):2361-9.</citation>
    <PMID>17117023</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>David Thomas</investigator_full_name>
    <investigator_title>Chief, Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
  <keyword>AIDS Virus</keyword>
  <keyword>Immunodeficiency Virus, Human</keyword>
  <keyword>Virus, Human Immunodeficiency</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, chronic</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Hepatitis C antibodies</keyword>
  <keyword>Hepatitis C antigens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Coinfection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

